TRAILR4/TNFRSF10D Antibody MAB633 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemTRAILR4/TNFRSF10D Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $599.00Supplier Page View Company Product Page
Catalog NumberMAB633
Quantity500 ug (also 25 ug)
ApplicationsFlow Cytometry,Neutralization,ELISA Capture (Matched Antibody Pair),CyTOF-ready
ReactivityHuman,Rat
Conjugate/TagUnconjugated
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
PurityProtein A or G purified from ascites
TargetTRAILR4/TNFRSF10D
HostMouse
IsotypeIgG1
Clone104918
Antibody TypePrimary Antibodies
NCBI Gene AliasesTRAILR4, CD264, DCR2, TRUNDD, TRAIL-R4
NCBI Full Gene NameTNF receptor superfamily member 10d
ClonalityMonoclonal
ImmunogenMouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D, Ala56-His211, Accession # Q9UBN6
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Specificity: Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF-alpha, and rhTNF¿ß is observed.

Sizes Available: 500 ug (also 25 ug)

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation StatusCancersOctober 26, 2022Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, et al.DR4/TRAIL-R1 (ALX-804-297F-T100), DR5/TRAIL-R2 (ALX-804-298F-T100), DcR1/TRAIL-R3 (MAB630), DcR2/TRAIL-R4 (MAB633) from R&D Systems (Minneapolis, MN, USA) and control IgG1 (BD Bioscience, Heidelberg, Germany). Cells

(2) Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of GlioblastomaMolecules (Basel, Switzerland)December 14, 2021Krishna Moorthy N, Seifert O, Eisler S, Weirich S, Kontermann RE, Rehm M, Fullstone G.anti-TRAILR2/TNFRSF10B (MAB6311, 1:100), mouse anti-TRAILR3/TNFRSF10C (MAB6302, 1:100), mouse anti-TRAILR4/TNFRSF10D (MAB633, 1:100), purified mouse IgG1 (1:100) and purified mouse IgG2b (1:100), purchased from R&D Systems (Wiesbaden-Nordenstadt,

(3) Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacyScientific reportsNovember 17, 2020Yoo JD, Bae SM, Seo J, Jeon IS, Vadevoo SMP, Kim SY, Kim IS, Lee B, Kim S.anti-human TRAIL receptor antibodies: MAB347 (anti-DR4), MAB6311 (anti-DR5), MAB6302 (anti-DcR1), and MAB633(anti-DcR2) (R&D Systems, Minneapolis, MN, USA)70. For cell binding analyses, A549 cells (4 × 105 cells)

(4) Targeting scFv-Fc-scTRAIL fusion proteins to tumor cellsOncotargetFebruary 16, 2018Hutt M, Fellermeier-Kopf S, Seifert O, Schmitt LC, Pfizenmaier K, Kontermann RE.anti-TRAIL-R2 (R&D Systems, MAB6311), anti-TRAIL-R3 (R&D Systems, MAB6301), anti-TRAIL-R4 (R&D Systems, MAB633) antibodies and moIgG1κ (BioLegend, 4001202), moIgG2aκ (BioLegend, 400202), moIgG2bκ (BioLegend, 401202)

(5) Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing stepsPloS oneJanuary 1, 2018Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N.

(6) Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarizationOncotargetAugust 28, 2015Suzuki-Karasaki Y, Fujiwara K, Saito K, Suzuki-Karasaki M, Ochiai T, Soma M.and mdivi-1 were obtained from Enzo Life Sciences (San Diego, CA). Anti-human TRAIL-R4 (clone 104918 #MAB633) and anti-human TRAIL-R5 (clone 71903 #MAB631) were purchased from R&D systems (Minneapolis, MN). Mouse

(7) Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexesThe Journal of biological chemistryJune 6, 2014Neumann S, Hasenauer J, Pollak N, Scheurich P.

(8) TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cellsAnticancer researchFebruary 1, 2014Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ, Zhang L.

(9) TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cellsCancer gene therapySeptember 1, 2012Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL.

(10) Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)Journal of cellular physiologyFebruary 1, 2010Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P.

(11) Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patientsBloodOctober 29, 2009Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, Quendler H, Kohrgruber N, Stingl G.

(12) Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cellsStem CellsNovember 1, 2008Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, et al.

(13) Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanismsMolecular cancer therapeuticsAugust 1, 2008Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK.

(14) P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cellsOncogeneJuly 10, 2008Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC.

(15) Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cellsJournal of cellular biochemistryMay 15, 2008Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C.

(16) A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosisCell death and differentiationApril 1, 2008Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M.

(17) Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosisMolecular cancer therapeuticsDecember 1, 2007Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM.

(18) Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cellsThe Journal of investigative dermatologyOctober 1, 2007Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Dürkop H, Sterry W, Eberle J.

(19) HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinomaOncogeneJuly 7, 2005Singh TR, Shankar S, Srivastava RK.

Be the First to Write a Review!

TRAILR4/TNFRSF10D Antibody

TRAILR4/TNFRSF10D Antibody

TRAILR4/TNFRSF10D Antibody

TRAILR4/TNFRSF10D Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (19)

Reviews

TRAILR4/TNFRSF10D Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map